BioSpace News Archive

While attending the 2023 BIO International Convention, Samsung Biologics, a leading contract development and manufacturing organization, revealed details of the company’s future expansion plan to have its new fifth plant operational by April 2025.

Akeso, Inc. (9926.HK) (“Akeso”) released two-year updated data from a Phase Ib/II clinical study of cadonilimab – a first-in-class PD-1/CTLA-4 bispecific antibody developed by Akeso – in combination with chemotherapy as first-line therapy for advanced gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

Theralase Technologies Inc. is pleased to announce the appointment of new independent director, Kaouthar Lbiati, M.D., M.Sc.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events.

To support stronger healthcare delivery and outcomes in West Africa, Shanghai Fosun Pharmaceutical Co., Ltd. announced a deepening partnership with IFC to help the company build a pharmaceutical production facility and distribution hub in Côte d’Ivoire.

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, announced that Proteologix US Inc. has been selected as the North American winner of its 12th Advance Biotech Grant program.

BIOREM Inc. announced $10.6 million of new orders for air emission abatement projects in North America.

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that HT-ALZ a therapeutic in development for the treatment of Alzheimer’s disease achieved positive preclinical results that outpaced its pervious study.

BioLife Solutions, Inc., a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapy and broader biopharma markets, announced the launch of a new, large-capacity controlled-rate freezer to expand its CRF product line, which now stands at three different form factors.

Edgewise Therapeutics, Inc. announced today that management will present at the Goldman Sachs Global Healthcare Conference on Tuesday, June 13, 2023, at 10 am PT (1 pm ET).